NTNatalya Petrovna Trubitsyna

Natalya Petrovna Trubitsyna

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Natalya Petrovna Trubitsyna has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sarcopenia in postmenopausal patients with type 1 diabetes mellitus: characteristics of functional, laboratory, and instrumental indicators

    by A. S. Zhdanova, Z. E. Belaya, M. S. Shamkhalova, N. V. Rusyaeva, A. A. Zhdanova, N. P. Trubitsyna, O. Y. Sukhareva, D. E. Mironenkov, L. I. Ibragimova, O. G. Melnikova, et al.

    BACKGROUND . Patients with type 1 diabetes mellitus (T1DM) are prone to earlier development of sarcopenia due to insulin deficiency, hyperglycemia, oxidative stress, and mitochondrial dysfunction. A pressing challenge in the management of these patients is the search for standardized diagnostic tools for the timely detection and monitoring of sarcopenia. OBJECTIVE . Comparative assessment of laboratory serum myokine levels in relation to muscle mass, strength, and function in postmenopausal women with type 1 diabetes and controls without diabetes. MATERIALS AND METHODS . A single-center, cross-sectional comparative study was conducted in women with type 1 diabetes (n=40) and a control group (n=40) aged 50–75 years. The SARC-F questionnaire, laboratory parameters (myostatin, follistatin, cystatin C, lipocalin 2, IGF-1), muscle mass (iDXA densitometry), strength (wrist dynamometry), and function (short-form exercise battery) were assessed. Statistical processing was performed in Statistica 14.0.0.15, IBM SPSS Statistics 23 using the Mann-Whitney, Fisher, and Spearman correlation tests. RESULTS . The age of the patients was 60 [56;64] years in the T1DM group and 64 [60;66] years in the control group (p=0.029). Glycated hemoglobin (HbA 1c ) in the T1DM group was 8.0% [7.6;9.3] with a diabetes duration of 26 [13;42] years. The myostatin level was significantly higher in T1DM 52.73 [46.45;58.26] mg/ml versus 21.46 [19.07;24.74] in the control (p < 0.001) and positively correlated with HbA 1c (r=0.544, p < 0.001), but not with muscle strength and mass. HbA1c negatively correlated with the time it took to get up from a chair 5 times. No differences were found in the levels of follistatin, lipocalin 2, cystatin C. Wrist dynamometry strength and walking speed were lower in the T1DM group with a tendency to statistical significance. The median IGF-1 was lower in diabetes (92.7 vs. 114.1 ng/ml, p=0.014) and positively correlated with muscle strength (r=0.472, p < 0.001). The sarcopenia index negatively correlated with muscle strength (r=-0.402, p=0.021) and positively with HbA 1c (r=0.514, p=0.035). Severe sarcopenia (according to EWGSOP2) was diagnosed in only one patient with T1DM, whose myostatin level did not differ from the range of patients without sarcopenia. CONCLUSION . Thus, patients with type 1 diabetes have higher myostatin levels, which correlates with with the level of HbA 1c . Low functional capacity in patients with type 1 diabetes is associated with HbA 1c levels, but is not directly related to myostatin levels.

  • Features of calcium-phosphorus metabolism and vitamin D metabolism in patients with chronic kidney disease at predialysis stages during bolus cholecalciferol therapy

    by A. S. Bondarenko, L. Ya. Rozhinskaya, A. Yu. Zhukov, V. A. Ioutsi, M. V. Ovcharov, G. S. Kolesnikova, A. I. Sleptsova, N. P. Trubitsyna, V. E. Vinogradov, O. N. Kotenko, et al.

    Background . Chronic kidney disease (CKD) is associated with disturbances in calcium-phosphate homeostasis and vitamin D metabolism, leading in mineral and bone disorders (CKD-MBD). However, the pathogenetic features of these alterations at predialysis CKD stages and the effects of high-dose cholecalciferol therapy remain insufficiently characterized. Objective . To compare vitamin D metabolites and calcium-phosphate metabolism parameters in patients with predialysis CKD and individuals without impaired kidney function, and to assess their dynamics after a single bolus dose of 150,000 IU of cholecalciferol. Materials and Methods . The study included 58 participants: 23 patients with CKD stage C3, 14 with CKD stages C4-5, and 21 controls. Parameters of calcium-phosphate metabolism and vitamin D metabolites were assessed at baseline and 7 days after a single oral dose of aqueous cholecalciferol (150,000 IU). Vitamin D metabolites were measured using LC–MS/MS. Results . Data are presented as follows: control group, CKD C3, CKD C4-5. At baseline, CKD patients had higher parathyroid hormone (PTH) levels (51.3 [40.6; 62.7] vs 70.9 [49.0; 105.9] vs 101.0 [91.7; 120.1] pg/mL), lower calcitriol concentrations (40.9 [34.3; 59.4] vs 25.0 [19.8; 29.1] vs 26.4 [13.8; 30.6] pg/mL), a trend toward higher fibroblast growth factor 23 (FGF-23) levels (0.73 [0.43; 1.07] vs 1.08 [0.61; 2.52] vs 3.22 [1.78; 4.51] pmol/L), and a reduced 24,25 (OH) 2 D 3 /25(OH)D 3 ratio (0.06 [0.04; 0.08] vs 0.03 [0.01; 0.04] vs 0.03 [0.02; 0.04]), indicating impaired 24-hydroxylase activity. Total and free 25(OH)D levels and vitamin D-binding protein (VDBP) were comparable between groups. Seven days after cholecalciferol administration, a similar increase in total 25(OH)D 3 , 3-epi-25(OH)D 3 , and 24,25(OH) 2 D 3 was observed in all groups. However, the increase in free 25(OH)D was significantly smaller in CKD C3 and C4-5 compared with controls ( p =0.036 and p =0.028). PTH decreased in CKD C3 ( p =0.039), whereas FGF-23 increased in CKD C4-5 ( p =0.042). Serum calcium, phosphorus, calcitriol, and VDBP remained unchanged. Conclusion . Alterations in calcium-phosphate and vitamin D metabolism at predialysis CKD stages show a sequential pattern. Reduced vitamin D activation and inactivation, increased FGF-23 levels, and a blunted free 25(OH)D response to bolus cholecalciferol indicate specific regulatory features and limit the applicability of standard vitamin D correction regimens in this population.

  • Open Access

    Markers of inflammation, fibrosis, endothelial dysfunction, and podocytopathy in patients with long-term type 1 diabetes mellitus

    by M. I. Yevloyeva, M. S. Arutyunova, L. V. Nikankina, A. I. Sleptsova, O. N. Naumenko, Z. T. Zuraeva, A. S. Severina, N. P. Trubitsyna, M. S. Shamkhalova, М. V. Shestakova

    BACKGROUND: A comprehensive assessment of biomarkers involved in the development of systemic inflammation in patients with long-term type 1 diabetes mellitus (T1D), accompanied by the development and progression of cardiac and renal pathology, may allow stratification of patients according to specific inflammatory activity and help in the search for new therapeutic prevention and treatment options.AIM: To evaluate markers of inflammation, fibrosis, endothelial dysfunction, and podocytopathy in patients with prolonged course of T1D (≥ 20 years).MATERIALS AND METHODS: The study consisted of 2 stages. In the first stage, a single-center, cross-sectional study of 133 patients was conducted. Of these, 87 patients with 10-year data available were included in the second stage of the study with dynamic assessment of parameters. All patients were examined and treated at the Endocrinology Research Centre of the Ministry of Health of Russia from 2011 to 2024. Patients were divided into several groups: without chronic kidney disease (CKD) and with CKD at different stages. In addition to standard laboratory parameters, the levels of matrix metalloproteinase-9 (MMP-9), brain natriuretic hormone (NT-proBNP), transforming growth factor beta-1 (TGF-β1), asymmetric dimethylarginine (ADMA), monocyte chemotactic factor-1 (MCP-1), osteopontin, and tumor necrosis factor receptors type 1 (TNFRSF1A) and type 2 (TNFRSF1B), cystatin C in blood, nephrin, podocin in urine were studied using commercial kits in accordance with manufacturers’ recommendations. Based on the values of the regression coefficients, the estimated glomerular filtration rate (eGFR) showed an inverse relationship with the development of chronic heart failure (CHF), while podocin exhibited a positive relationship with acute kidney injury (AKI). The risk of CHF decreased with every 1 mL/min/1.73 m² increase in eGFR, OR=1.12 (95% CI: 1.02–1.22, P=0.015). The risk of AKI increased with every 1 ng/mL increase in podocin level, OR = 1.43 (95% CI: 1.01–2.03, P=0.047).RESULTS: According to the criteria of CKD, preserved kidney function was observed in 43.2% of patients (n=54), the rest were at various stages of CKD. The prevalence of late complications of diabetes among the examined patients was high and increased as renal dysfunction progressed. Individuals with CKD showed increased levels of ADMA (PCONCLUSION: In individuals with a long history of T1D, a significant role of factors of endothelial dysfunction, inflammation and fibrosis, podocytopathy in the development and progression of CKD with involvement of the cardiovascular system in the pathological process has been determined.

  • Open Access

    Chronic kidney disease in patients with diabetes mellitus: new challenges

    by M. S. Shamkhalova, O. Y. Sukhareva, S. A. Martynov, A. S. Severina, O. K. Vikulova, N. P. Trubitsyna, O. N. Naumenko, N. V. Zaytseva, M. V. Shestakova, I. I. Dedov, et al.

    Chronic kidney disease (CKD) is a supranosological concept, defined as a disorder of the structure and/or function of the kidneys for 3 months or more that leads to health consequences. CKD develops in 20–40% of patients with diabetes mellitus (DM). Dynamic analysis of epidemiological indicators of CKD in patients with diabetes mellitus points to the prevalence increase of this pathology in the Russian Federation in 2010–2022. Improved quality of diagnostics of earlier stages complications, a decrease in the risk of cardiovascular events (the leading cause of death) and end-stage renal failure at a later age and with a longer duration of diabetes are noted as well. The development of tools for predicting the risk of the pathology progression and its complications has made it possible to improve patient monitoring and routing. Current international and domestic recommendations emphasize a comprehensive approach to the treatment of CKD, including lifestyle modification, evidence-based pharmacological treatments aimed at preserving organ function, and improving cardiovascular prognosis. An optimal model of care for patients with diabetes and CKD, aimed at multidisciplinary care and adapted according to the severity of CKD, will lead to the best outcomes for the individual patient and society.


  • Open Access

    Follow up of clinical outcomes in type 1 diabetic patients according to the results of dynamic examination in the mobile center "Diamobil"

    by Olga K. Vikulova, Anna V. Zheleznyakova, Daria V. Kutakova, Maria A. Startseva, Mikhail A. Isakov, Aleksey A. Serkov, Anastasiia P. Pershina-Miliutina, Natalia P. Trubitsyna, Elizaveta M. Matsiuk, Natalia B. Smirnova, et al.

    Background. Type 1 diabetes mellitus (T1DM) is a severe disease associated with reduced life expectancy. Understanding the causes and methods of reducing risks for this cohort is highly relevant for developing measures to reduce the number of years lost. Aim. To assess clinical outcomes: the frequency of diabetic complications, structure of mortality among T1DM patients who were examined at dynamic examination in the mobile center "Diamobil" in the Arkhangelsk region in 2005 and 2023. Materials and methods. The study was conducted on a cohort of patients with T1DM, examined at "Diamobil" in Arkhangelsk region in 2005 (n=319), with dynamic follow up of vital and clinical status, clinical parameters and frequency of complications over an 18-year period. At 2023, out of 319 people in the primary cohort – 61 patients died, 206 were in "alive" status and 52 were removed from analysis. Statistical analysis is performed with the help of Statistics v.13.3. Results. In the dynamic cohort (n=206) at 2023 median age of patients was 40 years [34; 55], duration of DM – 28 years [24; 33], percentage of women – 55%. Compared to 2005, glycated hemoglobin was comparable, there were an increase in body mass index (21.9 kg/m2 vs 25.1 kg/m2) and obesity rate from 3.1 to 11.2% (p=0.006), a decrease in estimated glomerular filtration rate (103.1 ml/min/1.73 mm2 vs 86.4 ml/min/1.73 mm2; p0.001) and increased frequency of diabetic complications: chronic kidney disease (CKD) any stage from 24.9 to 69.4%, Stage 3a CKD from 0.5 to 7.4% (p=0.003), diabetic retinopathy from 26.4 to 74.6%, diabetic neuropathy from 25.9 to 78.2% (p0.001), which reflects the long-term effect of the hyperglycemia factor. Based on the results of the analysis of mortality structure by proximal cause, it was established that the most frequent causes of death were cardiovascular disease – myocardial infarction, acute cerebral circulation disorder, heart failure and other cardiovascular diseases – 42.6%; death due to hypoglycemic and ketoacidotic coma – 3.2%, terminal cardiovascular disease – 14.8%. Deceased patients were characterized by a longer duration of DM (13 years vs 8 years), higher glycated hemoglobin (9.4% vs 8.4%), lipid profile (total cholesterol 4.77 mmol/l vs 4.41 mmol/l; TG 1.31 mmol/l vs 0.98 mmol/l) and albuminuria (70 mg/mmol vs 6 mg/mmol; p0.001). Conclusion. "Diamobil" control epidemiological studies can be positioned as the optimal method of risk cohort survey coverage for the assessment of dynamic indicators in real clinical practice.

  • Open Access

    Features of pregnancy after simultaneous pancreas-kidney transplantation in patient with type 1 diabetes mellitus. Case report

    by Madina I. Yevloyeva, Darya U. Savitskaya, Anastasia S. Severina, Minara S. Shamkhalova, Natalia P. Trubitsyna, Marina V. Shestakova, Савицкая Дарья Юрьевна, Трубицына Наталья Петровна

    Simultaneous pancreas and kidney transplantation the best way to restore normoglycemia and renal function in patients with type 1 diabetes mellitus and terminal chronic kidney disease. Pregnant patients after simultaneous pancreas and kidney transplantation are a high-risk group for adverse events/loss of both fetal and grafts. These risks are significantly reduced with pregnancy planning, regular monitoring of the woman and fetus with timely correction of immunosuppressive therapy, maintenance of target blood pressure and glycemia, selection of optimal timing and method of delivery. The presented clinical case demonstrates the need for an comprehensive multidisciplinary approach to the management of pregnancy and delivery with minimization of potential risks for mother and child.

  • Open Access

    Features of insulin therapy in combination of long-term type 1 diabetes mellitus and metabolic syndrome

    by M. D. Samsonova, N. P. Trubitsyna, A. S. Severina, M. S. Shamkhalova

    Type 1 diabetes mellitus (T1DM) continues to struggle with medical and social problems due to its high prevalence, polymorphism, development of severe diseases and irreversibility of changes. Despite four options for algorithms and choice of insulin therapy, the difficult task of switching to the insulin resistance (IR) scheme due to the impossibility of using drugs from the biguanide and glitazone group, since their use in T1DM is not provided for by the instructions. The presented observation shows the clinical picture of IR against the background of metabolic syndrome and prolonged hyperglycemia in patients with T1DM and special attention is paid to the importance of prescribing adequate insulin therapy and an individual approach to patient management. The main strategy in this case is a gradual increase in the insulin dose until the target glycemic indicators are achieved. At the same time, after achieving adequate doses and the patient staying within the near-target indicators for a certain period of time, it is possible to use insulin restrictions against the background of neutralizing the effect of glucotoxicity on peripheral tissues.


  • Open Access

    Chronic kidney disease in patients with long-term type 1 diabetes mellitus

    by M. I. Yevloyeva, M. S. Arutyunova, A. S. Severina, N. P. Trubitsyna, N. V. Zaitseva, M. S. Shamhalova, M. V. Shestakova

    BACKGROUND: Patients with type 1 diabetes mellitus (T1D) have an earlier age of onset and a longer course of the disease, already by middle age they have the development of microand macrovascular diabetic complications that reduce the quality and duration of life.AIM: To evaluate the prevalence of chronic kidney disease (CKD) and other late complications of T1D depending on renal dysfunction in the population of patients with T1D with disease duration of 20 and more years, who underwent examination and treatment in Endocrinology Research Centre.MATERIALS AND METHODS: A one-stage single-center epidemiological non-randomised study was conducted using the database of Endocrinology Research Centre with the study of 500 patients’medical histories with long-term T1D (20 years and mores), without kidney damage and with CKD at different stages (CKD C1–C5, C5D, after transplantation), examined and treated from 2011 to 2023.RESULTS: Normal renal function was observed in 10.8% of patients (n=54). Terminal stage of CKD was reached in 28.0% (n=140), of which 12.4% were on renal replacement therapy with program hemodialysis (RRT-HD), and 12.0% after isolated kidney transplantation or combined kidney and pancreas transplantation, the rest were at different stages of CKD. Normoalbuminuria was observed in 15.4% (n=77) among 500 patients. The prevalence of late complications of DM among the examined patients was high and increasing with the progression of renal dysfunction: diabetic retinopathy was diagnosed in 96% of patients, distal symmetrical polyneuropathy — in 97% of patients, various forms of autonomic neuropathy — in more than half of patients. About 60% of patients had diagnosed arterial atherosclerosis in the legs, about one third — atherosclerosis of brachiocephalic arteries, 23% — confirmed coronary heart disease, and suffered cardiovascular events (myocardial infarction, acute cerebral circulation disorder) — 19% of patients, about half of whom had CKD of different severity. Factors for increased risk of cardiovascular disease: estimated glomerular filtration rate (eGFR)2, OR=7.1; 95% CI 3.6–8.4; p2 OR=8.7; 95% CI 2.8–8.4; p2 OR=14; 95% CI 6.3–31.3; p 30 mg/g OR=2.4; 95% CI 1.6–3.6; pCONCLUSION: Despite a significant reduction in the risk of developing CKD in individuals with T1D debut between 1996 and 2002, renal dysfunction is a frequent complication in patients with a long disease course, combining with other late complications and contributing to a high risk of terminal stage of CKD and cardiovascular events. Early age of T1D debut increases the risk of terminal CKD.


  • Open Access

    Chronic kidney disease in patients with type 2 diabetes: new targets of medicine action

    by N. P. Trubitsyna, N. V. Zaitseva, A. S. Severinа, M. S. Shamkhalova

    Diabetes mellitus type 2 (DM2) is socially important disease, becoming non-infectious epidemic due to increasing prevalence. Chronic kidney disease (CKD) is one of the most common diabetic complications. Kidney injury signs and/or estimated glomerular filtration rate (eGFR) decrease are seen in 40-50% of patients with DM2. Three groups of factors are considered to be the basis of CKD development and progression in DM2: metabolic, hemodynamic, inflammation and fibrosis. Existing drugs that are used in patients with CKD and DM2 first of all target hemodynamic and metabolic disturbances, but their action against inflammation and fibrosis is indirect. Hyperactivation of mineralocorticoid receptors (MR) is considered as one of the main trigger factors of end-organ damage in patients with DM2 due to inflammation and fibrosis. Development of selective nonsteroidal MR antagonists (MRA) as a new class of medications is directed to demonstrate positive effects from blocking this pathophysiological pathway of CKD development and overcome the steroidal MRAs’ shortcomings. Hence pathophysiological hyperactivation of MR with subsequent inflammation and fibrosis in patients with CKD in DM2 is considered a promising therapeutic target for the new drugs with cardionephroprotective effect.


  • Open Access

    A simultaneous pancreas-kidney transplantation for type 1 diabetes mellitus after a long-term of receiving hemodialysis renal replacement therapy. Clinical сase

    by R. Kh. Salimkhanov, M. I. Yevloyeva, A. S. Severina, M. Sh. Shamkhalova, N. P. Trubitsyna, Y. G. Moysyuk, Я. Г. Мойсюк

    At the present time, a simultaneous pancreas-kidney transplantation (SPKT) is an effective method of treatment for patients on renal replacement therapy by hemodialysis program in the outcome of the terminal stage of diabetic nephropathy. This method of treatment solves several problems: it reduces the severity of intoxication syndrome, contributes to the achievement of euglycemia in most cases, which certainly allows to slow the progression of micro- and macrovascular complications of diabetes. Despite of positive effect of euglycaemia and kidney function normalization, the accumulated metabolic memory legacy of long-term uncompensated diabetes mellitus is realized, which makes a posttransplantational rehabilitation of patients difficult. A duration of hemodialysis therapy is known as a cardiovascular events risk factor, which affects the surgery result and favorable posttransplant period. More often after successful SPKT microvascular diabetic complications are stabilized, but macrovascular diabetic complications, diabetic neuroosteoarthropathy and mineral and bone disease are progressed. That’s why is necessary to perform regular examination after SPKT by a team of specialists, including nephrologist, endocrinologist, cardiologist, ophthalmologist with correction of ongoing therapy. Therefore both the preparation of the patient for transplantation with the earliest possible placement on the waiting list and the post-transplant rehabilitation afterwards are extremely important.